Clinical Study
Reestablishment of Active Immunity against HBV Graft Reinfection after Liver Transplantation for HBV-Related End Stage Liver Disease
Table 4
Characteristics of the 4 HBV-reinfected patients.
(a) |
| Case | Subtype of HBV | Mutation in the region of HBV polymers | Mutation in the region of HBV gene S | Mutation in the region of HBV gene PreS/S | BCP mutation | HBV DNA before OLT (copies/mL) | Antiviral agent before OLT | A1762T | G1764A | G1896A |
| 1 | C1 | — | P120PQ, M133MT, G145R | — | Negative | Negative | Negative | negative | LAM | 2 | C2 | — | — | — | Negative | Negative | Negative | | LAM | 3 | B2 | N236T | Q129R | PreS2 TGTACTTTC (46–54 nt) deletion | Positive | Positive | Negative | negative | ETV | 4 | B2 | — | G145R | — | Negative | Negative | Negative | | ADV |
|
|
(b) |
| Case | Vaccine type | Number of doses for reestablishment of immunity | Antiviral agent after OLT | Interval of time between withdrawal of nucleoside analogues and HBV reinfection (month) |
HBV DNA at the time of HBV reinfection (copies/mL) | Current antiviral agent | Current HbsAg | Current HBV DNA (copies/mL) |
| 1 | Twinrix | 5 | ADV | 12 | | TDF | Positive | Negative | 2 | Twinrix | 6 | ADV | 6 | | ETV | Positive | Negative | 3 | Twinrix | 10 | ETV | 16 | < | ETV | Negative | Negative | 4 | Engerix-B | 6 | ADV | 23 | | TDF | Positive | |
|
|